You are describing **histamine**, a crucial biogenic amine involved in a vast array of physiological processes.
Here's a breakdown of its structure, importance, and research applications:
**Structure:**
* **1-(3,4-dihydroxyphenyl)-2-(1-imidazolyl)ethanone** is the IUPAC name for histamine, a molecule with two key components:
* **Imidazole ring:** A five-membered ring containing two nitrogen atoms.
* **Ethanolamine side chain:** Contains a hydroxyl group (OH) and an amine group (NH2) attached to an ethane backbone.
* **3,4-dihydroxyphenyl group:** A benzene ring with two hydroxyl groups at positions 3 and 4.
**Importance:**
Histamine plays a vital role in various physiological processes:
* **Immune Response:** Released by mast cells and basophils during allergic reactions, triggering vasodilation (blood vessel expansion), bronchoconstriction (narrowing of airways), and inflammation.
* **Neurotransmission:** Functions as a neurotransmitter in the brain, influencing alertness, sleep-wake cycles, appetite, and other cognitive processes.
* **Gastric Acid Secretion:** Stimulates the release of gastric acid in the stomach, crucial for digestion.
* **Regulation of Blood Pressure:** Contributes to the regulation of blood pressure by influencing blood vessel dilation and constriction.
**Research Importance:**
Histamine's involvement in diverse biological functions makes it a significant target for research:
* **Drug Development:**
* **Antihistamines:** Medications blocking histamine receptors are used to treat allergies, allergic rhinitis, and motion sickness.
* **Anti-inflammatory drugs:** Drugs targeting histamine pathways are explored for treating inflammatory diseases like asthma and rheumatoid arthritis.
* **Neurological Disorders:** Investigating histamine's role in neurotransmission and its potential link to neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Gastrointestinal Disorders:** Understanding histamine's influence on gastric acid secretion is crucial for developing treatments for peptic ulcer disease and gastroesophageal reflux disease (GERD).
* **Cardiovascular Research:** Studying histamine's role in blood pressure regulation and potential connections to cardiovascular diseases.
* **Cancer Research:** Investigating histamine's potential contribution to tumor growth and development.
**In summary,** 1-(3,4-dihydroxyphenyl)-2-(1-imidazolyl)ethanone, or histamine, is a crucial molecule with a wide range of biological activities. Its involvement in various physiological processes makes it a significant target for research in fields ranging from allergies and inflammation to neurology, gastroenterology, and cardiovascular health.
ID Source | ID |
---|---|
PubMed CID | 52780 |
CHEMBL ID | 349641 |
CHEBI ID | 92075 |
Synonym |
---|
MLS-0315813.0001 |
MLS-0315813.0002 , |
MLS-0315813.0003 |
smr001382684 |
MLS002460467 |
CHEMBL349641 , |
1-(3,4-dihydroxyphenyl)-2-imidazol-1-ylethanone |
NCGC00247370-01 |
HMS2218C04 |
HMS3329J09 |
1-(3,4-dihydroxyphenyl)-2-(1-imidazolyl)ethanone;hydrochloride |
bdbm41887 |
1-(3,4-dihydroxyphenyl)-2-imidazol-1-yl-ethanone;hydrochloride |
1-(3,4-dihydroxyphenyl)-2-imidazol-1-ylethanone;hydrochloride |
cid_25067472 |
1-[3,4-bis(oxidanyl)phenyl]-2-imidazol-1-yl-ethanone;hydrochloride |
cid_52780 |
CHEBI:92075 |
1-(3,4-dihydroxyphenyl)-2-(1-imidazolyl)ethanone |
Q27163870 |
Class | Description |
---|---|
aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 35.4813 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 22.3872 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 56.2341 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 50.1187 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 39.8107 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 44.6684 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 37.9330 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.1250 | 16.2603 | 74.8000 | AID1056 |
alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | IC50 (µMol) | 17.7850 | 0.1100 | 11.3862 | 67.2000 | AID1017; AID1512 |
Alkaline phosphatase, tissue-nonspecific isozyme | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0150 | 2.2407 | 8.6000 | AID459065 |
Alkaline phosphatase, germ cell type | Homo sapiens (human) | IC50 (µMol) | 1.2000 | 0.6000 | 0.9000 | 1.2000 | AID459068 |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.2000 | 0.0005 | 3.3142 | 49.5000 | AID1017 |
Phospholipase A-2-activating protein | Homo sapiens (human) | IC50 (µMol) | 2.1000 | 0.0110 | 1.5370 | 2.5000 | AID459064 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID459066 | Inhibition of IAP by analogous luminescence assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | Design and synthesis of selective inhibitors of placental alkaline phosphatase. |
AID113962 | Anticonvulsant activity by the maximal electroshock test in mice by intraperitoneal administration | 1981 | Journal of medicinal chemistry, Jun, Volume: 24, Issue:6 | Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles. |
AID459068 | Inhibition of GCAP by analogous luminescence assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | Design and synthesis of selective inhibitors of placental alkaline phosphatase. |
AID459070 | Selectivity ratio of IC50 for GCAP to IC50 for PLAP | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | Design and synthesis of selective inhibitors of placental alkaline phosphatase. |
AID117081 | Lethal dose in mice determined after intraperitoneal administration. | 1981 | Journal of medicinal chemistry, Jun, Volume: 24, Issue:6 | Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles. |
AID459071 | Selectivity ratio of IC50 for TNAP to IC50 for PLAP | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | Design and synthesis of selective inhibitors of placental alkaline phosphatase. |
AID113963 | Anticonvulsant activity was evaluated by the maximal electroshock test in mice, administered orally | 1981 | Journal of medicinal chemistry, Jun, Volume: 24, Issue:6 | Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles. |
AID459069 | Selectivity ratio of IC50 for IAP to IC50 for PLAP | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | Design and synthesis of selective inhibitors of placental alkaline phosphatase. |
AID459065 | Inhibition of TNAP by analogous luminescence assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | Design and synthesis of selective inhibitors of placental alkaline phosphatase. |
AID459064 | Inhibition of PLAP by analogous luminescence assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2 | Design and synthesis of selective inhibitors of placental alkaline phosphatase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |